Trump's Order to Split the MMR Recommends Vaccines Nobody Makes

President Trump signed an executive order Monday recommending that American children receive vaccines that, at the moment, no company on Earth manufactures for the U.S. market. The order, unveiled in the Oval Office with Health Secretary Robert F. Kennedy Jr. at his side, establishes what the White House calls "Gold Standard" childhood vaccine recommendations¹: a routine schedule of 11 diseases instead of the 18 the CDC recommended in 2024, immunizations spread across separate medical visits, and the combined measles-mumps-rubella shot split into three single-disease vaccines. The order itself concedes the catch², conditioning the MMR split on such products becoming "domestically available." None are. Merck stopped making its standalone measles, mumps, and rubella vaccines in 2009⁶, at the request of pediatricians and the CDC's own advisers, and no manufacturer has announced plans to bring them back.

So the question worth answering is not whether the order is controversial (it is; the Republican chairman of the Senate health committee, physician Bill Cassidy, wrote that² "breaking up vaccines will mean children have to get more shots to get the same protection"). The question is whether an executive order can actually change what shots American children get. Trace the mechanism and the answer is: not this one, not soon, and possibly never in the form its authors imagine.

Start with who legally controls the schedule. The childhood immunization schedule is not a presidential document. It flows from the Advisory Committee on Immunization Practices, or ACIP, the expert panel whose votes, once adopted by CDC leadership, become official federal recommendations. Those recommendations are load-bearing in a way few advisory opinions are: under the Affordable Care Act, an ACIP recommendation obligates private insurers to cover a vaccine with no cost-sharing¹³, the federal Vaccines for Children program buys shots for Medicaid-eligible and uninsured kids based on ACIP's list, and nearly 600 state statutes and regulations⁹ across 49 states reference ACIP for everything from school-entry requirements to pharmacists' authority to give shots.

The administration already tried to rewrite that schedule once, and a federal court stopped it. In March, Judge Brian Murphy of the District of Massachusetts issued a preliminary injunction⁴ in a suit brought by the American Academy of Pediatrics and other medical groups, staying HHS's January schedule cut from 18 diseases to 11, suspending Kennedy's 13 handpicked ACIP appointees as likely violations of the Federal Advisory Committee Act, and nullifying every vote the reconstituted panel had taken. The court's reasoning leaned on the statutory linkages⁵ Congress built between ACIP and coverage law: CDC leadership cannot simply rewrite the schedule without the committee's genuine involvement. Monday's order recommends the same 11-disease schedule the injunction froze. An executive order cannot override a standing injunction; it can only instruct the agency to try again.

Then there is the factory problem, which no legal maneuver touches. Only combined MMR products are licensed in the United States. Reviving single-antigen versions would require new clinical trials, reconfigured production lines, and three separate FDA approvals⁷, a process the American Academy of Pediatrics estimates would take about a decade⁸. The order gives HHS 90 days to present a plan for offering single vaccines while guaranteeing that combination vaccines stay available³. A plan for a product that arrives in the mid-2030s is an aspiration, not a policy.

I want to be careful here, because the argument for taking this order seriously is better than the mockery suggests. It goes like this: the injunction was procedural, not permanent. The HHS Secretary lawfully appoints ACIP's members. If the administration eventually seats a committee that survives court review, holds properly noticed votes, and adopts them, the very architecture that blocks the order today becomes its transmission belt. Those 600 state laws that reference ACIP would update automatically in many states; VFC purchasing and ACA coverage would follow the new schedule as a matter of law; and federal procurement dollars could de-risk monovalent manufacturing that no company would fund on its own. On paper, that is a genuine pathway, and it is why I would not call this order a nullity. It is a directive to keep pulling on levers that really exist.

But the past year shows those levers snapping off in the administration's hands, and each pull weakens the machine it needs. The insurers who actually pay for pediatric vaccines have defected from the fight: AHIP, the industry's main trade group, committed in May that member plans will keep covering all ACIP-recommended vaccines with no cost-sharing through the end of 2027¹¹, pegged to the recommendations as they stood in September 2025, before Kennedy's panel began downgrading them. The pediatricians have built a parallel authority, with the AAP rolling out its own independent immunization guidance¹² and lining up commercial payers behind it. And the states are cutting the cord: in 2026 alone, at least eight states enacted laws¹⁰ reducing or removing ACIP's role in their insurance mandates, pharmacist authority, and vaccine purchasing, with California amending more than 25 statutes to defer to its own health department instead. The order's transmission belt is being dismantled in real time, largely in reaction to the administration's earlier overreach. Even the White House seems to know it, since the order resorts to advising states to rewrite their school-entry laws and directing the attorney general to challenge limits on exemptions, which is what you do when the federal channel is closed.

What the order can do, immediately, is change behavior, and here the historical record is grim. Japan withdrew its combined MMR in 1993 and, even with single-antigen vaccines available, saw immunization rates fall; a 2001 epidemic produced roughly 265,000 measles cases⁷. Splitting one visit into three multiplies the chances a dose is missed: delays early in the series strongly predict¹ a child missing the MMR entirely by age 2. A presidential endorsement of spacing and splitting does not need legal force to persuade an anxious parent to wait.

And this is the worst possible year for waiting. The CDC has confirmed 2,465 measles cases and 38 new outbreaks in 2026¹⁴, already past 2025's total and the most since 1991¹⁵, with the Pan American Health Organization set to review this fall whether the United States loses the measles elimination status it has held since 2000. So consider the actor this order actually reaches: a parent in Utah or South Carolina, states carrying the year's biggest outbreaks, sitting in a pediatrician's office this month. If she follows the president's guidance and asks to hold off until a measles-only shot exists, she is deferring real protection for a product that is at best a decade away. The order cannot rewrite the schedule this year, but it can talk her out of following it, and in 2026 that is the only power it has.